Use of two general-purpose scales to assess clinical pharmacy activities in a cell transplantation unit.
| Title: | Use of two general-purpose scales to assess clinical pharmacy activities in a cell transplantation unit. |
|---|---|
| Authors: | Quinet F; CHU Lille, Institut de Pharmacie, Lille, France.; Gilliot S; CHU Lille, Institut de Pharmacie, Lille, France.; Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.; Beauvais D; CHU Lille, Maladie du Sang, Unité de Thérapie Cellulaire, Lille, France.; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.; Vasseur M; CHU Lille, Institut de Pharmacie, Lille, France.; Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.; Srour M; CHU Lille, Maladie du Sang, Unité de Thérapie Cellulaire, Lille, France.; Magro L; CHU Lille, Maladie du Sang, Unité de Thérapie Cellulaire, Lille, France.; Coiteux V; CHU Lille, Maladie du Sang, Unité de Thérapie Cellulaire, Lille, France.; Chauvet P; CHU Lille, Maladie du Sang, Unité de Thérapie Cellulaire, Lille, France.; Yakoub-Agha I; CHU Lille, Maladie du Sang, Unité de Thérapie Cellulaire, Lille, France.; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.; Odou P; CHU Lille, Institut de Pharmacie, Lille, France.; Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.; Décaudin B; CHU Lille, Institut de Pharmacie, Lille, France.; Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.; Simon N; CHU Lille, Institut de Pharmacie, Lille, France.; Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France. |
| Source: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2026 Apr; Vol. 32 (3), pp. 507-514. Date of Electronic Publication: 2024 Nov 25. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : SAGE Publications; Original Publication: Norwalk, CT : Appleton & Lange, c1995- |
| MeSH Terms: | Pharmacy Service, Hospital*/organization & administration ; Pharmacists*/organization & administration ; Hematopoietic Stem Cell Transplantation*/methods ; Drug-Related Side Effects and Adverse Reactions*/epidemiology ; Drug-Related Side Effects and Adverse Reactions*/prevention & control; Drug Monitoring/methods ; Humans ; Retrospective Studies ; France ; Professional Role ; Drug Interactions ; Female ; Male |
| Abstract: | IntroductionThe general-purpose rating scales used by clinical pharmacists to rate their activities have not been extensively studied in specialist care units. This study aims to describe drug-related problems (DRPs) and pharmacist interventions (PIs) in a French hematopoietic cell therapy (HCT) unit and to evaluate the PIs' likely clinical, economic, and organizational impacts.MethodsWe retrospectively assessed all DRPs reported and all PIs issued between December 2018 and December 2021. The Act-IP scale was used to rate DRPs and PIs, and the ClEO scale was used to rate each PI's clinical, economic and organizational impacts. Fisher's exact test was used to assess the relationships between PIs and DRPs and between the three dimensions of the ClEO scale.ResultsThe DRPs were most frequently related to drug-drug interactions (16.5%), physicochemical incompatibilities (15.5%), and drug monitoring problems (14.9%). 62.8% of the PIs had at least a moderate clinical impact. PIs that recommended drug monitoring were most frequent (26.8%), and most of these (75%) were likely to have prevented incidents that would have required patient monitoring or treatment.ConclusionsThe results of this study showed that after a slight adaptation, the Act-IP scale can be used to map clinical pharmacy activity in an HCT unit. More than 60% of the DRPs/PIs were likely to have had a positive impact on the patient's clinical outcome. All the PIs were rated with a positive organizational impact and PIs likely to lead to cost savings were balanced by those likely to increase costs. |
| Competing Interests: | Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Contributed Indexing: | Keywords: Clinical pharmacy; drug therapy; hematopoietic cell transplantation |
| Entry Date(s): | Date Created: 20241125 Date Completed: 20260420 Latest Revision: 20260420 |
| Update Code: | 20260420 |
| DOI: | 10.1177/10781552241297391 |
| PMID: | 39584735 |
| Database: | MEDLINE |
Journal Article